Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 2/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.40 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867993 | 1.00 | LOX (0.47) | LOXLOXL2FFAR1ACACBHCRTR1 | |
| SCHEMBL7021012 | 0.87 | GAK (0.39) | LOXLOXL2FFAR1ACACBHCRTR1 | |
| SCHEMBL34466348 | 0.87 | EGLN2 (0.38) | LOXLOXL2FFAR1HCRTR1HCRTR2 | |
| SCHEMBL4930416 | 0.81 | GABRG2 (0.49) | ACACBHCRTR1HCRTR2ARGRM5 | |
| SCHEMBL13571312 | 0.80 | NUDT1 (0.46) | LOXLOXL2FFAR1ACACBHCRTR1 | |
| SCHEMBL17276076 | 0.80 | ACACB (0.47) | FFAR1ACACBHCRTR1HCRTR2GRM5 | |
| SCHEMBL14855815 | 0.80 | FFAR1 (0.49) | LOXLOXL2FFAR1ACACBHAO1 | |
| SCHEMBL3577009 | 0.80 | LOX (0.47) | LOXLOXL2FFAR1ACACBHCRTR1 | |
| SCHEMBL3924934 | 0.79 | ACACB (0.47) | ACACBHCRTR1HCRTR2GRM5CLK4 | |
| SCHEMBL4929558 | 0.79 | ACACB (0.41) | FFAR1ACACBHCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260109692-A1 | KCNT1 INHIBITORS AND METHODS OF USE | UCB Biopharma SRL (BE) | 2026-04-23 | — | — | US | disclosed |
| EP-4727942-A2 | THIAZOLOPYRIDIN-7(4H)-ONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025137599-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206738-A1 | WRN INHIBITORS | NIMBUS DISCOVERY, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-0004793-B1 | 2-NITRO AMINOPYRIMIDONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE TO PREPARE 2-AMINOPYRIMIDONE DERIVATIVES WHICH HAVE HISTAMINE H2-ANTAGONIST ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-30 | — | — | EP | disclosed |
| US-4305945-A | Isoureas and isothioureas | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-15 | — | — | US | disclosed |
| EP-0003677-B1 | PYRIMIDONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-11-11 | — | — | EP | disclosed |
| US-4255428-A | ANTIINFLAMMATORY AGENTS, HISTAMINE BLOCKING AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-03-10 | — | — | US | disclosed |
| US-4234588-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-11-18 | — | — | US | disclosed |
| EP-0017680-A1 | Pyrimidone derivatives, process for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-29 | — | — | EP | disclosed |
| US-4227000-A | Intermediates in the process for making histamine antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| EP-0007232-A1 | Iso(thio)ureas, processes for their preparation and compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-01-23 | — | — | EP | disclosed |
| EP-0004793-A2 | 2-nitro aminopyrimidone derivatives, a process for their preparation and their use to prepare 2-aminopyrimidone derivatives which have histamine H2-antagonist activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-10-17 | — | — | EP | disclosed |
| EP-0003677-A2 | Pyrimidones, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206738-A1 | WRN INHIBITORS | WRN, BLM, RECQL | LOX 3098/4885LOXL2 3170/4885FFAR1 4538/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | LOX 1263/4885LOXL2 2718/4885FFAR1 172/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | LOX 1208/4885LOXL2 2837/4885FFAR1 135/4885 |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | LOX 921/4885LOXL2 1013/4885FFAR1 271/4885 |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | LOX 921/4885LOXL2 1013/4885FFAR1 271/4885 |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | LOX 1331/4885LOXL2 2285/4885FFAR1 244/4885 |
| US-20260109692-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNJ2, KCNT2 | LOX 1994/4885LOXL2 1334/4885FFAR1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.